Poxel SA, which is developing treatments for diabetes, has appointed Pierre Legault as chairman of its board of directors, succeeding Thierry Hercend who will continue as a board member. Mr Legault has more than 35 years of experience in the pharma and biotech industries and currently serves on the boards of three US-based companies. During his career he has held executive positions at Eckerd Corp, NephroGenex Inc and OSI Pharmaceuticals Inc, now part of Astellas Pharma.
Poxel announced the appointment on 18 April 2016.
Copyright 2016 Evernow Publishing Ltd